Limited visibility inside bioreactors is a persistent drain on productivity and margins in industrial biotechnology. BioSee AI, developed at the University of Nottingham, offers a practical path to continuous, actionable monitoring without the complexity or cost of traditional inline systems.
AI Solves Biotech’s Real-time Monitoring Gap
Bioprocess operators routinely lack frequent, reliable measurements of key culture parameters. That gap raises the risk of batch failures, product variability and wasted raw materials. BioSee AI addresses this by providing continuous, non-invasive sensing and AI-driven interpretation that delivers early warning of contamination or quality drift and predicts process parameters over time.
How BioSee AI Leverages AI and Sensing for Bioprocess Insight
The platform combines low-cost ultrasonic and optical sensors mounted externally with machine learning models that translate raw signals into biologically relevant metrics. Because sensors are non-invasive and retrofit-friendly, the system can be added to existing bioreactors without process interruption. Real-time data streams feed trained algorithms that infer critical variables, spot anomalies, and forecast trends that help operators reduce batch failures, cut waste, and improve yield consistency across applications such as alternative proteins and waste valorisation.
Expanding Access and Future-Proofing Biomanufacturing
BioSee AI is designed for affordability and broad deployment. A notable feature is its federated learning approach, which allows models to improve across multiple sites while keeping proprietary process data local. That privacy-preserving capability lowers barriers for small and medium-sized enterprises to adopt advanced monitoring. The project has attracted funding and industry partners and is preparing industrial pilot trials and market discovery work to scale adoption.
For biotech decision-makers and investors, BioSee AI signals a shift: smarter, cheaper monitoring that raises yields and reduces risk without demanding large capital expenditure. The next steps are pilots, wider commercial testing, and integration into biomanufacturing workflows where real-time insight translates directly to cost savings and more reliable production.
